ARRAY BIOPHARMA INC Form 8-K April 29, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2004

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-31979	84-1460811		
(State or Other	(Commission	(IRS Employer		
Jurisdiction of	File Number)	Identification No.)		
Incorporation)				

3200 Walnut Street, Boulder, Colorado80301(Address of Principal Executive Offices)(Zip Code)

Registrant s telephone number, including area code: (303) 381-6600

(Former Name or Former Address, if Changed Since Last Report)

ITEM 5.	OTHER	EVENTS	AND	REQUIRED	FD	DISCLOSURE.
	OHILL	EVENIE	$\Delta \mathbf{I} \mathbf{I} \mathbf{D}$	KEQUIKED	\mathbf{I}	DISCLOSURE.

On April 29, 2004, the Registrant issued a press release announcing the appointment of Douglas E. Williams, Ph.D., to its Board of Directors, the full text of which is attached hereto as Exhibit 99.1.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(c) Exhibits.

Press release dated April 29, 2004 entitled Array BioPharma Appoints Douglas E. Williams, Ph.D., To Its Board Of Directors.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARRAY BIOPHARMA INC.

Date: April 29, 2004 By: /s/ Robert E. Conway
Robert E. Conway

Chief Executive Officer

3

EXHIBIT INDEX

Exhibit No.

99.1 Press release dated April 29, 2004 entitled Array BioPharma Appoints Douglas E. Williams, Ph.D., To Its Board Of Directors.

4